PV
54 programs · 53 companies
Programs
54
Companies
53
Trials
53
MOAs
35
CAR-T BCMAGLP-1/GIPCD3xCD20MALT1iEZH2iBiTECDK2iALKiIL-17iIL-13i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Phase 2 | TYK2 | ||
| JNJ-8168 | Phase 2/3 | FLT3 | ||
| LLY-1184 | NDA/BLA | C5 | ||
| ABB-8985 | Phase 2 | CD20 | ||
| AZN-5171 | Approved | GLP-1R | ||
| NVO-9615 | Phase 2/3 | PRMT5 | ||
| Bemarelsin | Preclinical | GLP-1R | ||
| MRN-7409 | NDA/BLA | SHP2 | ||
| ALN-3284 | Phase 2/3 | CDK2 | ||
| ARG-3458 | Preclinical | RET | ||
| ROI-3353 | Phase 1/2 | PLK4 | ||
| RVM-274 | Phase 3 | MET | ||
| Motanaritide | Approved | PD-1 | ||
| Capirapivir | Approved | JAK2 | ||
| CRS-337 | Phase 2/3 | PARP | ||
| Terazumab | Phase 2 | BTK | ||
| Lisosotorasib | Phase 2/3 | CDK4/6 | ||
| Mavulucimab | NDA/BLA | AHR | ||
| IPS-9466 | NDA/BLA | TROP-2 | ||
| Adagralemzoparlimab | Approved | HER2 | ||
| GOS-5370 | Phase 2/3 | TNFα | ||
| Lisocagene | Phase 2/3 | CFTR | ||
| PBL-3756 | Phase 1/2 | KRASG12D | ||
| ACE-6753 | Phase 2/3 | EZH2 | ||
| Olpatenlimab | Phase 1/2 | AuroraA | ||
| BIO-9035 | Phase 2/3 | MDM2 | ||
| Doxazanubrutinib | Phase 3 | MALT1 | ||
| CLE-136 | Phase 3 | PARP | ||
| 996-4673 | Phase 1/2 | APOC3 | ||
| QUA-2029 | Phase 1/2 | PRMT5 | ||
| FRE-IIT-815 | NDA/BLA | PRMT5 | ||
| PLR-762 | Approved | JAK1 | ||
| Sotolucimab | Phase 2/3 | LAG-3 | ||
| Riboosocimab | Phase 2 | TYK2 | ||
| Semaglumide | Phase 3 | SGLT2 | ||
| 006-348 | Phase 1/2 | CD38 | ||
| TOR-2843 | Phase 1/2 | Menin | ||
| Mirirasimod | NDA/BLA | PLK4 | ||
| 219-3907 | Approved | LAG-3 | ||
| Talazanubrutinib | Phase 1/2 | MDM2 | ||
| RNA-7525 | Phase 2/3 | TYK2 | ||
| SPR-5098 | Phase 2 | CD20 | ||
| Fixalucimab | NDA/BLA | HER2 | ||
| Kemavorutinib | Phase 2/3 | CDK2 | ||
| Ivomavacamten | Phase 1/2 | AHR | ||
| DAR-2860 | Phase 1 | GLP-1R | ||
| MOL-8666 | Approved | WEE1 | ||
| BAY-3810 | Phase 2/3 | CD123 | ||
| BCA-2794 | Approved | KIF18A | ||
| Rimabrutinib | Phase 1 | IL-13 | ||
| TAT-IIT-383 | Phase 3 | Menin | ||
| Mavuzumab | NDA/BLA | IL-23 | ||
| Tixainavolisib | Phase 3 | PLK4 | ||
| WAT-1779 | Phase 1 | KRASG12D |
Trials (53)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04722586 | Voxacilimab | Phase 2 | Terminated |
| NCT03086036 | Voxacilimab | Phase 2 | Active |
| NCT08590954 | JNJ-8168 | Phase 2/3 | Not yet recr... |
| NCT05723959 | LLY-1184 | NDA/BLA | Completed |
| NCT06984051 | AZN-5171 | Approved | Active |
| NCT05454960 | AZN-5171 | Approved | Completed |
| NCT06501995 | AZN-5171 | Approved | Active |
| NCT07194762 | NVO-9615 | Phase 2/3 | Not yet recr... |
| NCT05831728 | NVO-9615 | Phase 2/3 | Terminated |
| NCT04157940 | Bemarelsin | Preclinical | Terminated |
| NCT06000171 | MRN-7409 | NDA/BLA | Completed |
| NCT03046557 | ALN-3284 | Phase 2/3 | Active |
| NCT03290166 | ARG-3458 | Preclinical | Active |
| NCT05618874 | Motanaritide | Approved | Not yet recr... |
| NCT04335443 | Motanaritide | Approved | Not yet recr... |
| NCT07770800 | Motanaritide | Approved | Not yet recr... |
| NCT06636735 | Capirapivir | Approved | Not yet recr... |
| NCT05643774 | Terazumab | Phase 2 | Terminated |
| NCT06754697 | IPS-9466 | NDA/BLA | Completed |
| NCT07125764 | Adagralemzoparlimab | Approved | Recruiting |